Stuart Allan Murray, M.S.12 Walkup Road, Sudbury, MA 01176

milesaheadbio@comcast.net339-223-9287

SummaryBiopharmaceutical executive with over 25 years experience as proven commercial strategist and developer of anti-biotics, anti-fungals and other acute care products. Science focused, market savvy and data driven approach to increasing asset valuation anywhere along life-cycle continuum, from early clinical development through genericization. Proven success leading departments, driving cross-functional teams and developing talent through periods of organizational growth and change.

Biopharmaceutical Industry Experience

MILES AHEAD BIOCONSULTING, LLC (Sudbury, MA) 2015 - PresentPresidentOffering a unique blend and range of consulting services within an integrated view of the healthcare arena to optimally strategize, plan and commercialize acute care assets. Consulting services include, but not limited to:

Pre-Commercial Product Planning o Identifying and assessing scientific, clinical and business attributes for sustainable

differentiationo Market research to support validated target product profileo Health economics, pricing and value proposition strategyo Commercial operations planning, including marketing, decision support and sales

functions Commercialization

o Healthcare provider and care setting segmentation strategyo Positioning and messaging to ensure sustainable differentiationo Strategic commercial resource allocation and communication planningo Current and future competitor assessments, including generics

Life-Cycle Value Optimizationo Product improvements (formulations, presentations, delivery systems, etc.)o Scientific development (indications, phase IV studies, IIS programs, registries,

health economics, etc.)o Market exclusivity extension strategies

CUBIST PHARMACEUTICALS, Inc. (Lexington, MA) 2003 – June, 2015(Acquired by Merck January 22, 2015)

Global Program Leader – Gram Positive Franchise (2010-2012; 2014-2015): Responsible for optimizing global life-cycle value of blockbuster CUBICIN® and recently launched SIVEXTRO® anti-infective assets

Led growth-phase life-cycle strategy and execution of CUBICIN® product development plan, optimizing value proposition and supporting revenue growth from $540M in 2010 to over $1B in 2014

Led global cross-functional teams with members located in Lexington MA, San Diego CA and Zurich CH.

Provided global leadership in coordination of CUBICIN® life-cycle strategies with alliance partners Novartis (EU), Merck (Japan) and for SIVEXTRO® with Bayer (ROW)

Led and executed comprehensive late-phase life-cycle strategy for CUBICIN® franchise in preparation for generic entry. Consulted internal experts, KOL’s and customers in identifying over 35 specific asset growth and defense strategies

o Devised multi-dimensional strategy to develop a new, innovative “attribute” (confidential), providing hospitals and home infusion companies with a better product of higher value vs. generic entrants

o Directed comprehensive valuation modeling, supported by robust market research, to determine ROI ranges across multiple future market scenarios

o Gained approval from Merck Executive Committee to advance multi-million dollar development plan

Led Senior Executive team in development and coordination of highly confidential organizational contingency plan in event Cubist lost a Paragraph IV generic challenge to Teva Pharmaceuticals in 2012. Plan detailed a down-sized organization strategy & structure, an Authorized Generic partnership and a systematic internal and external communication plan

Head of Program Management - Interim (2013): Led department of nine through integration of Optimer and Trius pharmaceutical companies and during sweeping organizational change toward a program centric operating model

Provided steady leadership during contentious organizational change from functional to program centric operating model. Constantly communicated, influenced and managed conflict with functional leaders during implementation phase. Persistently and deftly garnered organizational support in embedding program model into organizational fabric

Provided guidance for programs spanning pre-clinical to commercial assets and across multiple therapeutic areas

As member of R&D Leadership Team & Portfolio Review Committees helped shape portfolio development priorities during time of extraordinary organizational growth

Coached and mentored Program Leaders and Program Managers through transition to program operational model

Senior Director, Marketing (2006-2009): Led department of nine during CUBICIN’s steepest growth phase

Grew revenues from $113.5M in 2005 to $540M in 2009 Devised strategy to establish sustainable scientific and product differentiation within

increasingly crowded competitive field and dynamic healthcare delivery systems Partnered with medical affairs, health economics, non-clinical and clinical development

departments to align strategy and drive generation of differential data resulting in countless peer-review publications that influenced IDSA guidelines, informed treatment pathways and enhanced value proposition

Led approval and launch of novel rapid injection administration, resulting in improved patient and care-giver convenience and domination of the out-patient infusion market

Successfully executed strategy with discipline, leveraging a $20M budget against a multitude of communication channels, including a 200-person sales force, peer-to-peer promotions, branding initiatives, advertising campaigns, electronic media and non-personal promotion

Promoted seven department members, including futures heads of Marketing, Medical Affairs & Sales Training

Director of Marketing (2003-2005): Key member of initial launch CUBICIN® Launch Team Solely responsible for outpatient marketing plan for initial launch, including application

for reimbursement codes, hiring and managing reimbursement support vendor and training of sales force on outpatient market segments. Outpatient market accounted for 25% revenue following year one of launch

Responsible for converting scientific data into marketing strategy. Vision behind and management of Infectious Disease KOL “summit” meeting, resulting in publication of

Supplement in Clinical Infectious Diseases (2006; 42:S1-61). Execution from concept to publication in 16 months

Led 16-month cross-functional effort in planning launch of an exclusive Staphylococcus aureus bacteremia indication

Led corporate compliance change initiative, resulting in sweeping changes to commercial policies and procedures Teamed with the Chief Compliance Officer to execute internal monitoring and external auditing practices

ALLOS THERAPEUTICS, INC. (Westminster, CO) 2000 – 2003 Associate Director, Corporate Development, OncologyManager, Corporate Development

Led efforts in identifying and evaluating over 200 global oncology compounds for potential in licensing. Managed multidisciplinary evaluation team, including over 15 KOL consultants, in assessing licensing candidates. Efforts led to two successful licensing deals in 2002

Identified, reviewed and nominated phase I pralatrexate, a folate analog metabolic inhibitor, for in licensing. Facilitated thorough due diligence, resulting in deal consummation within 5 months of compound identification. Note: Pralatrexate (Folotyn®) was FDA approved September 28, 2009

Intimately involved in out-licensing efforts for phase III radiosensitizer RSR-13

GILEAD SCIENCES/NEXSTAR PHARMACEUTICALS (Boulder, CO) 1997 - 2000Product Manager, AmBisome®

1998 - 2000 Lead liaison with Fujisawa in U.S. co-marketing partnership for flagship product,

AmBisome® Developed growth strategies and tactics, revised positioning and core messages to

infectious disease and hematological audiences. AmBisome® generated $77 million in U.S. sales in 2000, a 45% increase from 1999

Senior Therapeutic Specialist, San Francisco Bay Area 1997 - 1998

Initiated and developed relations with national thought leaders in antifungal therapy at Stanford University and the University of California, San Francisco

IMMUNEX CORPORATION (San Francisco, CA) 1995 - 1997 Oncology Representative

Successfully promoted cytokines and chemotherapeutics to oncologists, hematologists, bone marrow transplant physicians at Stanford University and University of California, San Francisco

JOHNSON & JOHNSON (Reno, NV) 1991 - 1995Professional Hospital Representative – Stanford Univeristy Hospitals

1994 - 1995Professional Sales Representative

1991 - 1994 Actively promoted IV antibiotics, analgesics and antipsychotics to Stanford University

Hospitals Inherited territory ranked #66 in total performance in Western U.S. Developed strategies

and tactics to drive growth, resulting in territory ranking #1 after just two years

CALIFORNIA STATE UNIVERSITY, CHICO BIOLOGY DEPARTMENT 1988 - 1991

STANFORD MEDICAL CENTER 1983 - 1987

Education

Master of Science, Biochemistry, California State University, Chico Bachelor of Arts, English, California State University, Chico